P. LoRusso

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

Andrés Cervantes, María Alsina, Josep Tabernero et al. · Journal of Clinical Oncology · 2011 · 54 citations

Solid Tumors, Liver Involvement, Novel Rnai Therapeutic +17

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

Daniel D. Von Hoff, P. LoRusso, G. D. Demetri et al. · Journal of Clinical Oncology · 2011 · 31 citations

Pathology, Pharmacotherapy, Tumor Biology +17

Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC)

Shirish M. Gadgeel, A. Wozniak, Martin J. Edelman et al. · Journal of Clinical Oncology · 2009 · 30 citations

Pathology, Pharmacotherapy, Neuro-oncology +21

A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

Cristian Moldovan, Jean‐Charles Soria, P. LoRusso et al. · Journal of Clinical Oncology · 2010 · 20 citations

Chemoprevention Strategy, Pathology, Pharmacotherapy +18

A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.

J. M. Cleary, Elisabeth I. Heath, E. L. Kwak et al. · Journal of Clinical Oncology · 2010 · 20 citations

Solid Tumors, Cancer Management, Next-generation Hsp90 Inhibitor +20